

APPENDICES

- I. BIOGRAPHIES OF SPEAKERS
- II. PARTICIPANTS ATTENDING SEMINAR 1
- III. THE BECKLEY FOUNDATION

BIOGRAPHIES OF SPEAKERS

COLIN BLAKEMORE

PhD, ScD, FIBiol, FMedSci, FRS

**Waynflete Professor of Physiology, University of Oxford
Director of the Oxford Centre for Cognitive Neuroscience**

Colin Blakemore studied medical sciences at Cambridge, completed a PhD at the University of California, Berkeley, taught at Cambridge for 11 years, and in 1979 took up the Chair of Physiology at the University of Oxford. He has received many prizes for his research, which has been concerned with vision and the early development of the brain, and he is currently President of the Physiological Society and President of the new Biosciences Federation. He is also passionately committed to the public communication of science and won the Royal Society Michael Faraday Medal in 1989. He has been President and is now Chairman of the British Association for the Advancement of Science. He is a frequent broadcaster on radio (including the BBC Reith Lectures) and television (including the Royal Institution Christmas lectures and *The Mind Machine*, a 13-part series on brain and mind). He has also written widely for the general public: his most recent book is *The Oxford Companion to the Body*. He has contributed to the national debate on drugs, arguing that assessment of harm should be soundly based on scientific evidence, and that we must contemplate more radical approaches to the problem.

T.W. ROBBINS

Department of Experimental Psychology, University of Cambridge

Trevor Robbins gained his first degree and PhD in Psychology from the University of Cambridge, the latter under the supervision of Dr Susan Iversen in Psychopharmacology. He was appointed initially to the faculty in 1973 at the University and gained tenure as a lecturer in 1978. He was appointed first as Reader in Cognitive Neuroscience (1992) and in 1997 as Professor of Cognitive Neuroscience. Recently, he has been elected to the Chair of Experimental Psychology (and HoD) at Cambridge from October 2002. He is a Fellow of the British Psychological Society (BPS) and the Academy of Medical Sciences. In 1982, he won the BPS Spearman Medal for outstanding research. In 1996 he shared the award of the DG Marquis medal for the best paper published that year in the APA journal *Behavioral Neuroscience*. In 1998 he delivered a Hebb Lecture to McGill University and the closing Plenary at FENS in Paris 2002. He has been President of the European Behavioural Pharmacology Society (1992-1994) and he won that Society's inaugural Distinguished Scientist Award in 2001. He was also President of the British Association of Psychopharmacology from 1996 to 1997. He has edited the journal *Psychopharmacology* since 1980 and until recently was Associate Editor of *Behavioral Neuroscience*. He has been a member of Medical Research Council (UK) and chaired the Neuroscience and Mental Health Board until 1999. He was included on a list of the 100 most cited neuroscientists by ISI. He has published over three hundred and fifty full papers and co-edited three books (*Psychology for Medicine: The Prefrontal Cortex; Executive and Cognitive Function, and Disorders of Brain and Mind*).

LESLIE IVERSEN
Department of Pharmacology, University of Oxford

Leslie Iversen PhD is Director of the Wolfson Centre for Research on Age Related diseases at Kings College London, Visiting Professor at the Department of Pharmacology, University of Oxford, and founder of the pharmaceutical company Panos Therapeutics Ltd. He was previously Director of the Neuroscience Research Centre set up by the international pharmaceutical company Merck & Co. Inc. in Harlow, Essex, UK (1983-1995) and Director of the UK Medical Research Council Neurochemical Pharmacology Unit in Cambridge, England (1970-1983). He is interested in understanding how drugs work in the nervous system and in the molecular basis of nervous system disorders and is particularly known for his work on the chemical messengers used for communication between nerve cells. He is the author of several books and of more than 350 scientific publications and is a Fellow of the Royal Society of London and a Foreign Associate of the National Academy of Sciences, USA. He acted as the specialist adviser to the House of Lords Science & Technology Committee's enquiry into Cannabis, and his most recent books are "The Science of Marijuana", Oxford University Press, 2000 and "A Very Short Introduction to Drugs", Oxford University Press, 2001.

BARRY J. EVERITT
Department of Experimental Psychology, University of Cambridge

Barry Everitt has a B.Sc. in Zoology and a Ph.D. in Behavioural Neuroendocrinology from the University of Birmingham Medical School in 1970. Following a postdoctoral position in neuroscience at the Karolinska Institute, he joined the Department of Anatomy at the University of Cambridge as a lecturer, then Reader in Neuroscience. In 1995, he moved to the Department of Experimental Psychology in Cambridge and was appointed to a personal Professorship in Behavioural Neuroscience in 1997. He has been President of the British Association for Psychopharmacology, President of the European Brain and Behaviour Society and is president-elect of the European Behavioural Pharmacology Society. He is also Editor-in-Chief of the European Journal of Neuroscience. His major research interests at present concern the neural and psychological basis of cocaine and heroin addiction, especially the importance of interactions between these drugs and learning systems in the brain which result in drug-seeking and drug-taking becoming compulsive habits. A key aspect of his research concerns the development of novel treatments for addiction based on preventing relapse when individuals are exposed to drug cues that induce craving.

DAVID J. NUTT
DM, FRCP, FRCPPsych, FMedSci
Department of Clinical Medicine, University of Bristol

David Nutt is currently Professor of Psychopharmacology, Head of the Department of Clinical Medicine and Dean of Clinical Medicine and Dentistry, based at the University of Bristol. He received his undergraduate training in medicine at Cambridge and Guy's Hospital, and continued training in neurology to MRCP. After completing his psychiatric training in Oxford, he continued there as a lecturer and then later as a Wellcome Senior Fellow in psychiatry. He then spent two years as Chief of the Section of Clinical Science in the National Institute of Alcohol Abuse and Alcoholism in NIH, Bethesda, USA. On returning to England in 1988 he set up the Psychopharmacology Unit in Bristol, an interdisciplinary research grouping spanning the departments of Psychiatry and Pharmacology. He is currently a member of the Advisory Council on the Misuse of Drugs, and Chair of the Technical Committee of the ACMD, the Committee on Safety of Medicines. In addition, he is advisor to the British National Formulary, the editor of the Journal of Psychopharmacology and the Past-President of the British Association of Psychopharmacology.

MARK A. GEYER
Department of Psychiatry, University of California, San Diego

Dr. Geyer is a preclinical psychopharmacologist at the University of California, San Diego, where he currently holds the position of Professor of Psychiatry and Neurosciences in the School of Medicine. He is actively involved in both the Ph.D. Group in Neurosciences and the Clinical Psychology Ph.D. Program. Since receiving his doctorate in Psychology in 1972, he has focused on basic research addressing the behavioral and neurobiological effects of drugs acting via monoaminergic neurotransmitters. For over two decades, he has had continuous funding from the U.S. National Institute on Drug Abuse to study the behavioral effects of hallucinogens in animals. Dr. Geyer is also internationally known for his research on the psychophysiology, neurobiology, and pharmacotherapy of schizophrenia, which is supported by multiple grants from the National Institute of Mental Health. He has published over 250 peer-reviewed papers, including many addressing the mechanisms subserving the effects of psychostimulants, hallucinogens, and entactogens. Dr. Geyer is currently an editor for two highly-respected international journals, *Psychopharmacology* and *Neuropharmacology*, and is on the Editorial Board of several other journals. Dr. Geyer was one of the co-founders of the Heffter Research Institute, which reviews and funds rigorous research on psychedelic compounds and publishes the Heffter Review. He is currently the President of the International Behavioral Neuroscience Society, Vice-President of the international Serotonin Club, and a member of the Scientific Council of NARSAD.

MICHAEL FARRELL
Consultant Psychiatrist, National Addiction Centre

Dr Michael Farrell, is a Senior Lecturer and Consultant Psychiatrist at the National Addiction Centre and Maudsley Hospital London. He is responsible for a large community based drug and alcohol service in South London. He is involved in research and policy aspects of drug and alcohol problems. He has conducted research on the relationship between drug, alcohol, tobacco use and other forms of psychiatric morbidity. He has conducted a range of treatment evaluation projects. He has worked in partnership with the Office in National Statistics on the programme of surveys of psychiatric morbidity which has included two national household surveys, a prisons survey, a homeless survey and a survey of child and adolescent mental health. He has worked part time as a policy advisor to the Department of Health. He is an editor with the Cochrane Collaboration Alcohol and Drugs Group involved in the review of effective interventions for drug and alcohol dependence. He has worked with a wide range of international organisations and is also a member of the WHO Expert Committee on Drug Dependence. He has published over 200 articles on aspects of tobacco, alcohol and drug use and dependence.

PARTICIPANTS WHO ATTENDED SEMINAR 1

Bob Ainsworth MP	<i>Parliamentary Under-Secretary of State for Anti-Drugs Co-ordination and Organised Crime</i>
Nick Barton	<i>Chief Executive, Clouds House</i>
Prof. Colin Blakemore	<i>Waynflete Professor of Physiology, University of Oxford</i>
Richard Brunstron	<i>Chief Constable of North Wales</i>
Yolande Burgin	<i>Director, The Independent Inquiry into Drug Testing at Work</i>
Eric Carlin	<i>Chief Executive of Mentor Foundation</i>
Dr. Mark Collins	<i>Associate Medical Director, The Priory, Roehampton</i>
Rod Dalley	<i>Vice Chairman Elect, Police Federation of England and Wales</i>
Richard Davenport-Hines	<i>Author 'The Pursuit of Oblivion, A Global History of Narcotics'</i>
Dr. Pat di Ciano	<i>Dept. of Psychology, University of Cambridge. Raconteur.</i>
Prof. Barry Everitt	<i>Professor of Behavioural Neuroscience, University of Cambridge</i>
Dr. Michael Farrell	<i>Consultant Psychiatrist, National Addiction Centre</i>
Prof. Cindy Fazey	<i>Professor of International Drug Policy, University of Liverpool</i>
Prof. Mark Geyer	<i>Professor of Psychiatry and Neurosciences, University of California</i>
Tony Gilland	<i>Director of Science and Society, Institute of Ideas</i>
Fulton Gillespie	<i>Parent</i>
Tony Hall	<i>Head of Drugs Legislation Section, Drugs Strategy Directorate, Home Office</i>
Paul Hayes	<i>Chief Executive, National Treatment Agency for Substance Misuse</i>
Roger Howard	<i>Chief Executive of Drugscope</i>
Prof. Leslie Iversen	<i>Professor of Pharmacology. University of Oxford. Author of 'The Science of Marijuana'</i>
Mike Jay	<i>Historian and Author</i>
Charlie Lloyd	<i>Joseph Rowntree Foundation</i>
Dr. José-Ramon Lopez-Portillo	<i>Former Chairman of the Council of the F.A.O. United Nations</i>

Dr. Athina Markou	<i>Department of Neuropsychopharmacology, The Scripps Research Institute</i>
Dr. John Marks	<i>Ran the Chapel Street Clinic, Liverpool</i>
Tristan Millington-Drake	<i>Chief Executive, The Chemical Dependency Centre</i>
Sir Keith Morris	<i>Former Ambassador of Columbia</i>
Amanda, Lady Neidpath	<i>Director, The Beckley Foundation</i>
Bill Nelles	<i>General Secretary, The Methadone Alliance</i>
Prof. David Nutt	<i>Professor of Psychopharmacology and Head of Department of Clinical Medicine, University of Bristol</i>
Brian Paddick	<i>Commander, Metropolitan Police</i>
Dr. Mark Peplow	<i>Science Information Officer, The Royal Institution</i>
Fredrick Polak MD	<i>Consultant Psychiatrist, Member of the Board of the Netherlands Drug Policy Foundation</i>
Fabrice Pothier	<i>Representative from NEF-EDPF</i>
Dr. Alex Richardson	<i>Senior Research Fellow, Physiology Department, Oxford</i>
Prof. Trevor Robbins	<i>Professor of Cognitive Neuroscience, University of Cambridge</i>
Ian Robinson	<i>Chief Executive of the E.A.T.A. (the European Association for the Treatment of Addiction)</i>
Dr. Phillip Robson	<i>Senior Research Fellow, Department of Psychiatry Oxford, Medical Director of G.W. Pharma</i>
Prof. John Stein	<i>Professor of Neurophysiology, Magdalen College Oxford</i>
Prof. Dai Stephens	<i>Professor Experimental Psychology, University of Sussex</i>
Charles Tallack	<i>Performance and Innovation Unit, Cabinet Office</i>
Mike Trace	<i>National Treatment Agency, and Chairman of European Monitoring Centre for Drugs and Drug Addiction, Lisbon</i>
Jan Wiarda	<i>Chief of Police, The Hague</i>
Sir Richard Wilson	<i>Master of Emmanuel College, Cambridge. Former Secretary of the Cabinet and Head of the Home Civil Service</i>

THE BECKLEY FOUNDATION

The Beckley Foundation is a charitable trust set up to promote the investigation of consciousness from the perspectives of science, health, politics and history. Its activities include supporting and directing research programs, seminars and conferences to inform researchers, professionals and the public.

It has a particular interest in the comparative study of changes in consciousness brought about by such diverse activities as the practice of yoga, meditation and some forms of exercise and nutrition, as well as the use of legal and illicit drugs.

- The Foundation's main scientific objective is to research the neurophysiology underlying changes in consciousness, especially those associated with heightened creativity, elevated awareness and positive mood.
- The Foundation's social objective is to promote public health by supporting world-class scientific research into consciousness and its modulation from a multi-disciplinary perspective; and by disseminating the information to academics, policy-makers and the public.

The Beckley Foundation particularly seeks to promote the understanding of how this knowledge may be used to enhance health, ameliorate mental and physical illness, and comfort the dying. It also aims to investigate how best to encourage the avoidance of those practices that lead to poor health and addiction.

A key aspect of the Foundation's activities is to support and organise seminars and conferences where leading experts from a wide range of disciplines can analyse and explore the social and health implications of the latest scientific knowledge. This seminar on 'Drugs and the Brain', held at Magdalen College, Oxford on 22 Oct 2002, is the first in the series entitled 'Society and Drugs: A Rational Perspective'.



THE BECKLEY FOUNDATION
BECKLEY PARK
OXFORD